Literature DB >> 23839278

Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action.

Jiasheng Hu1, Xiongpeng Zhu, Quanyi Lu.   

Abstract

OBJECTIVES: To investigate the effects of γ-secretase inhibitor (GSI), a Notch signalling inhibitor, on the proliferation of multiple myeloma cells in vitro and its molecular mechanism of action.
METHODS: RPMI 8226 cells were treated with increasing concentrations of GSI (0-20 µmol/l) for 24-72 h. Proliferation was measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay. Cell-cycle analysis was performed on RPMI 8226 cells treated with 0-10 µmol/l GSI for 48 h using flow cytometry. Expression of Notch signalling proteins (Notch1, Jagged 1 and Jagged 2), Bcl-2 and phosphorylated Akt (p-Akt) was determined using Western blotting in RPMI 8226 cells treated with various concentrations of GSI for various time periods.
RESULTS: GSI inhibited proliferation of RPMI 8226 cells in a concentration- and time-dependent manner by inducing G0/G1 cell-cycle arrest. GSI-mediated antiproliferative effects were associated with significant reductions in the expression of Notch1, Jagged1, Jagged2, p-Akt and Bcl-2.
CONCLUSION: Inhibition of the Notch signalling pathway by GSI may be a promising therapeutic approach for the treatment of multiple myeloma.

Entities:  

Keywords:  Multiple myeloma; Notch signalling pathway; phosphoinositide 3-kinase/Akt pathway; proliferation; γ-secretase inhibitor

Mesh:

Substances:

Year:  2013        PMID: 23839278     DOI: 10.1177/0300060513485912

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  6 in total

1.  A Gli inhibitor GANT61 suppresses cell proliferation, promotes cell apoptosis and induces G1/G0 cycle retardation with a dose- and time-dependent manner through inhibiting Notch pathway in multiple myeloma.

Authors:  Zhihua Zhang; Changlai Hao; Rongjuan Zhang; Xiaochuan Pei; Jundong Li; Lihong Wang
Journal:  Cell Cycle       Date:  2020-07-17       Impact factor: 4.534

2.  FOXP3 expression is modulated by TGF‑β1/NOTCH1 pathway in human melanoma.

Authors:  Eva Skarmoutsou; Valentina Bevelacqua; Fabio D' Amico; Angela Russo; Demetrios A Spandidos; Aurora Scalisi; Grazia Malaponte; Claudio Guarneri
Journal:  Int J Mol Med       Date:  2018-04-04       Impact factor: 4.101

3.  [Clinical significance of S100A6 and Notch1 in multiple myeloma patients].

Authors:  H Y Bao; Y Wang; J N Wang; M Song; Q Q Meng; X Han
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

4.  FLI-06 Intercepts Notch Signaling And Suppresses The Proliferation And Self-renewal Of Tongue Cancer Cells.

Authors:  Rui-Huan Gan; Li-Song Lin; Jing Xie; Li Huang; Lin-Can Ding; Bo-Hua Su; Xian-E Peng; Da-Li Zheng; You-Guang Lu
Journal:  Onco Targets Ther       Date:  2019-09-18       Impact factor: 4.147

5.  Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells.

Authors:  Efstathia Giannopoulou; Achilleas Nikolakopoulos; Dimitra Kotsirilou; Angeliki Lampropoulou; Sofia Raftopoulou; Evangelia Papadimitriou; Achilleas D Theocharis; Thomas Makatsoris; Konstantinos Fasseas; Haralabos P Kalofonos
Journal:  J Biomed Sci       Date:  2015-10-24       Impact factor: 8.410

6.  Notch-1 Confers Chemoresistance in Lung Adenocarcinoma to Taxanes through AP-1/microRNA-451 Mediated Regulation of MDR-1.

Authors:  Jiayuan Huang; Yitian Chen; Junyang Li; Kai Zhang; Jing Chen; Dongqin Chen; Bing Feng; Haizhu Song; Jifeng Feng; Rui Wang; Longbang Chen
Journal:  Mol Ther Nucleic Acids       Date:  2016-10-11       Impact factor: 10.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.